Pentraxin-3 and Outcomes in CKD: A Systematic Review and Meta-analysis

Li, Li; Liu, Hongli; Zhang, Qinglin; Jin, Hao; Tao, Hui; Chen, Hongmei; Zhou, Zhongwei

doi:10.1016/j.xkme.2024.100800

Kidney Medicine

2024

DOI: 10.1016/j.xkme.2024.100800

|View full text |Cite

Pentraxin-3 and Outcomes in CKD: A Systematic Review and Meta-analysis

Li Li,

Hongli Liu,

Qinglin Zhang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Involvement of pentraxin‐3 in the development of hypertension but not left ventricular hypertrophy in male spontaneously hypertensive rats

Mkhize,

Manilall,

Mokotedi

et al. 2024

Physiological Reports

View full text Add to dashboard Cite

Hypertension drives the development of concentric left ventricular hypertrophy (LVH). However, the relative contribution of pentraxin‐3 (PTX‐3), a novel marker for inflammatory cardiovascular disease, in the hypertrophic response to pressure overload has not been adequately elucidated. We investigated the role of PTX‐3 in the development of LVH in spontaneously hypertensive rats (SHR), untreated and treated with either captopril (an ACE inhibitor) or hydralazine (a non‐specific vasodilator). Three‐month‐old SHR received either 20 mg/kg/day hydralazine (SHR + H, n = 6), 40 mg/kg/day captopril (SHR + C, n = 6), or plain gelatine cubes (untreated SHR, n = 7) orally for 4 months. Wistar Kyoto rats (WKY, n = 7) were used as the normotensive controls. Blood pressure (BP) was measured using the tail‐cuff method. Cardiac geometry and function were determined using M‐mode echocardiography. Circulating concentrations of inflammatory markers were measured in plasma by ELISA. LV fibrosis and cardiomyocyte width were assessed by histology. Relative mRNA expression of PTX‐3 was determined in the LV by RT‐PCR. Untreated SHR exhibited greater systolic BP and relative wall thickness (RWT) compared to WKY. Captopril and hydralazine normalized BP but only captopril reversed RWT in SHR. Circulating PTX‐3 and VCAM‐1 levels were elevated in untreated SHR and reduced with captopril and hydralazine. Circulating PTX‐3 was positively associated with systolic BP but lacked independent relations with indices of LVH. LV relative mRNA expression of PTX‐3 was similar between the groups. PTX‐3 may not be involved in the development of LVH in SHR, but plausibly reflects the localized inflammatory milieu associated with hypertension.

show abstract

Involvement of pentraxin‐3 in the development of hypertension but not left ventricular hypertrophy in male spontaneously hypertensive rats

Mkhize,

Manilall,

Mokotedi

et al. 2024

Physiological Reports

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pentraxin-3 and Outcomes in CKD: A Systematic Review and Meta-analysis

Cited by 1 publication

References 33 publications

Involvement of pentraxin‐3 in the development of hypertension but not left ventricular hypertrophy in male spontaneously hypertensive rats

Involvement of pentraxin‐3 in the development of hypertension but not left ventricular hypertrophy in male spontaneously hypertensive rats

Contact Info

Product

Resources

About